Fosun Pharma invests in PE fund, plans vaccine unit spinoff

Shanghai Fosun Pharmaceutical Group's subsidiary, Fosun Pharma Industrial, is investing RMB 10 billion in a new private equity fund. This fund, with a target size of RMB 100 billion, will focus on innovative drugs, biologics, high-end medical devices, and other strategic emerging sectors. This investment aligns with Fosun Pharma's strategy to leverage its and CR Pharmaceutical's strengths in the healthcare sector.

Simultaneously, Fosun Pharma plans to spin off its vaccine platform, Fosun Antigene (Chengdu) BioPharmaceutical, for a separate listing on the Hong Kong Stock Exchange. This move aims to enhance Fosun Antigene's financing channels and market competitiveness while deepening Fosun Pharma's presence in the vaccine sector. This will not affect Fosun Pharma's control over Fosun Antigene or its overall financial performance.

In related news, Fosun Pharma also adjusted its 2025 estimated annual caps for certain daily connected transactions, increasing the limit for services accepted from Fosun International and its associates by RMB 2 billion to RMB 9 billion due to increased business needs.